About me
Jennifer Low, MD, PhD, is the Head of Therapeutics Development at 23andMe. She oversees the transition of potential therapeutics from 23andMe's research laboratories into clinical development studies, and leads a group that includes preclinical and clinical development and drug manufacturing.
Jennifer has over thirty years of drug development experience spanning academia, government, large pharma and small biotech. She has been the Chief Medical Officer and Executive Vice President of Research and Development at Loxo Oncology where she oversaw the clinical development of Vitrakvi (Trk inhibitor). Prior to that, she led or oversaw the Erivedge (hedgehog), Zelboraf (b-RAF), Cotellic (mek), among many other clinical development programs at Genentech, a member of the Roche Group.
She received her undergraduate degree from Caltech, her M.D. and Ph.D. degrees from Georgetown, and completed her internal medicine residency at the University of California Davis, her medical oncology fellowship at the National Cancer Institute, and was a Senior Investigator at the Cancer Therapeutics Evaluation Program at NCI and an attending physician in breast cancer at the National Institutes of Health and the National Naval Medical Center in Bethesda. She has co-authored papers appearing in the New England Journal of Medicine, Science, Cancer Discovery, Journal of Clinical Oncology, and Nature Reviews Cancer.